Published in Thromb Haemost on July 01, 1999
Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci (2016) 0.88
Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke. Cardiovasc Ultrasound (2005) 0.84
Temporal changes in circulating P-selectin, plasminogen activator inhibitor-1, magnesium, and creatine kinase after percutaneous coronary intervention. J Zhejiang Univ Sci B (2010) 0.83
Recurrent thrombosis after mechanical circulatory support. Interact Cardiovasc Thorac Surg (2012) 0.77
Granulocyte-endothelium initial adhesion. Analysis of transient binding events mediated by E-selectin in a laminar shear flow. Biophys J (1993) 2.86
C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia (2007) 2.19
Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes (2000) 1.92
The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia (2009) 1.82
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation (1996) 1.80
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood (1988) 1.68
Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost (2007) 1.67
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol (2000) 1.64
Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes (1997) 1.60
Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study. Neurology (2011) 1.57
Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation (2004) 1.52
Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol (1998) 1.47
Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost (1987) 1.44
Influence of residual myocardial ischaemia on induced ventricular arrhythmias following a first acute myocardial infarction. Eur Heart J (2001) 1.43
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia (1991) 1.41
Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin. Thromb Haemost (1989) 1.38
Cutaneous necrosis associated with acquired severe protein S deficiency. Thromb Haemost (1993) 1.37
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism (1986) 1.30
Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood (2001) 1.24
Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation (1997) 1.21
Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med (2000) 1.16
PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost (1997) 1.16
Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J (1995) 1.12
Iloprost and salvage of a free flap. Br J Plast Surg (1996) 1.09
Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol (2002) 1.08
[Value of systematic preventive antibiotherapy in cardiac pacemaker implantation]. Ann Cardiol Angeiol (Paris) (1991) 1.08
Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol (2006) 1.07
Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and nontreated episodes. Metrix Investigators. J Am Coll Cardiol (2000) 1.06
Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology (1997) 1.04
Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood (1996) 1.02
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells. Infect Immun (1990) 1.02
Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol (2007) 1.02
Ouabain binding sites and (Na+,K+)-ATPase activity in rat cardiac hypertrophy. Expression of the neonatal forms. J Biol Chem (1986) 1.01
Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr (1992) 1.00
The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost (2003) 1.00
Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. Int J Obes (Lond) (2011) 0.97
Two Na,K-ATPase isoenzymes in canine cardiac myocytes. Molecular basis of inotropic and toxic effects of digitalis. J Biol Chem (1987) 0.97
Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol (1997) 0.97
Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab (1987) 0.96
Adipose tissue expression of gelatinases in mouse models of obesity. Thromb Haemost (2001) 0.96
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis (1989) 0.96
[Heart perforation following transvenous implantation of a cardiac pacemaker]. Presse Med (1999) 0.96
Incidence of perforation and other mechanical complications during dual active fixation. Pacing Clin Electrophysiol (1996) 0.95
Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol (1998) 0.94
Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol (2005) 0.93
Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism (1989) 0.93
Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia (2001) 0.93
PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol (1999) 0.92
Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost (1993) 0.92
Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisol. Thromb Haemost (1985) 0.91
Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med (1996) 0.91
Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol (1997) 0.91
Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care (1998) 0.90
Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats. J Nutr (1999) 0.90
Fat cell function and fibrinolysis. Horm Metab Res (2001) 0.90
[Wolff-Parkinson-White syndrome. Correlation between the results of electrophysiological investigation and exercise tolerance testing on the electrical aspect of preexcitation]. Arch Mal Coeur Vaiss (1979) 0.89
Protein S deficiency and HIV infection. N Engl J Med (1991) 0.89
Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost (1987) 0.89
Two functional Na+/K(+)-ATPase isoforms in the left ventricle of guinea pig heart. Eur J Biochem (1991) 0.88
External cardioversion of atrial fibrillation: comparison of biphasic vs monophasic waveform shocks. Europace (2001) 0.88
Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. Int J Obes (Lond) (2009) 0.88
Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells. Indications that calcium acts at a translational level. Arterioscler Thromb Vasc Biol (1997) 0.88
Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men. Am J Physiol Endocrinol Metab (2007) 0.88
Alteration of Na,K-ATPase isoenzymes in diabetic cardiomyopathy: effect of dietary supplementation with fish oil (n-3 fatty acids) in rats. Diabetologia (1997) 0.88
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest (1993) 0.86
Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease. Int J Cardiol (2001) 0.86
Genetics of the PTS components in Escherichia coli K-12. FEMS Microbiol Rev (1989) 0.86
Modulation of mouse cerebral Na+,K(+)-ATPase activity by oxygen free radicals. Neuroreport (1995) 0.86
Fibrinolytic function and coronary risk. Curr Cardiol Rep (1999) 0.85
Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord (1998) 0.85
Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: the PRIME study. Atherosclerosis (2011) 0.84
Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis (2004) 0.84
Two active Na+/K+-ATPases of high affinity for ouabain in adult rat brain membranes. Biochim Biophys Acta (1990) 0.84
Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. Blood (1996) 0.84
Internal low-energy cardioversion: a therapeutic option for restoring sinus rhythm in chronic atrial fibrillation after failure of external cardioversion. Europace (1999) 0.84
Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost (1992) 0.83
Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost (1994) 0.83
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes (1999) 0.83
[Percutaneous electric interruption of normal auriculoventricular conduction. Analysis of French cases]. Arch Mal Coeur Vaiss (1986) 0.82
Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost (2003) 0.82
A high calorie diet induces type 2 diabetes in the desert sand rat (Psammomys obesus). Cell Mol Biol (Noisy-le-grand) (2007) 0.82
Treatment of hepatitis C patients with normal aminotransferases levels. Clin Liver Dis (1999) 0.81
The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol (2000) 0.81
Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost (1986) 0.81
Catheter ablation using very high frequency current: effects on the atrioventricular junction and ventricular myocardium in sheep. Europace (2002) 0.81
Ginkgo biloba extract (EGb 761) protects Na,K-ATPase activity during cerebral ischemia in mice. Neuroreport (1999) 0.81
[In vitro malignant transformation of fetal hamster brain cells by benzo (a) pyrene]. C R Acad Sci Hebd Seances Acad Sci D (1976) 0.81
Vitamin D metabolism, functions and needs: from science to health claims. Eur J Nutr (2012) 0.81
Anti-arrhythmic effects of I (Na), I (Kr), and combined I (Kr)-I (CaL) blockade in an experimental model of acute stretch-related atrial fibrillation. Cardiovasc Drugs Ther (2007) 0.81
In vivo assessment of murine elastase-induced abdominal aortic aneurysm with high resolution magnetic resonance imaging. Eur J Vasc Endovasc Surg (2012) 0.81
Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost (2001) 0.81
Formation, inhibition and clearance of plasmin in vivo. Haemostasis (2001) 0.80
[Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases]. Rev Med Interne (2001) 0.80